Next Article in Journal
Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation
Next Article in Special Issue
Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site
Previous Article in Journal
Proton Beam Therapy without Fiducial Markers Using Four-Dimensional CT Planning for Large Hepatocellular Carcinomas
Previous Article in Special Issue
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Open AccessFeature PaperEditor’s ChoiceReview

Update on Immunohistochemistry for the Diagnosis of Lung Cancer

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
Cancers 2018, 10(3), 72; https://doi.org/10.3390/cancers10030072
Received: 3 February 2018 / Revised: 9 March 2018 / Accepted: 13 March 2018 / Published: 14 March 2018
(This article belongs to the Special Issue Immunohistochemistry and Cancer Diagnosis)
Immunohistochemistry is a widely available technique that is less challenging and can provide clinically meaningful results quickly and cost-efficiently in comparison with other techniques. In addition, immunohistochemistry allows for the evaluation of cellular localization of proteins in the context of tumor structure. In an era of precision medicine, pathologists are required to classify lung cancer into specific subtypes and assess biomarkers relevant to molecular-targeted therapies. This review summarizes the hot topics of immunohistochemistry in lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine markers; (iii) ALK, ROS1, and EGFR; (iv) PD-L1 (CD274); (v) lung carcinoma vs malignant mesothelioma; and (vi) NUT carcinoma. Major pitfalls in evaluating immunohistochemical results are also described. View Full-Text
Keywords: immune checkpoint; immunostaining; INSM1; morphology; non-small cell lung carcinoma (NSCLC); pathology; thoracic tumor; small cell lung carcinoma (SCLC); tyrosine kinase; WHO classification immune checkpoint; immunostaining; INSM1; morphology; non-small cell lung carcinoma (NSCLC); pathology; thoracic tumor; small cell lung carcinoma (SCLC); tyrosine kinase; WHO classification
Show Figures

Figure 1

MDPI and ACS Style

Inamura, K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers 2018, 10, 72.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop